Which antibiotic can be used for MRSA and penicillin-resistant streptococcal infections?

Clindamycin is the correct choice for treating MRSA (Methicillin-Resistant Staphylococcus Aureus) and penicillin-resistant streptococcal infections due to its effectiveness against certain Gram-positive bacteria. This antibiotic works by inhibiting bacterial protein synthesis, making it particularly useful for treating skin and soft tissue infections caused by MRSA. It is also effective against streptococci that have developed resistance to penicillin, providing a viable alternative for such infections.

Clindamycin's ability to penetrate well into tissues, including abscesses, also enhances its utility in treating infections that require deeper tissue reach, common in MRSA infections. Given the increasing prevalence of antibiotic resistance, particularly with MRSA, clindamycin serves as an important option in the arsenal against resistant infections.

While ciprofloxacin, vancomycin, and rifampin have their own indications, they either do not provide sufficient coverage for MRSA or penicillin-resistant streptococcus or are not the first-line choice for these infections. Ciprofloxacin primarily targets Gram-negative bacteria, making it less suitable for these types of infections. Vancomycin is effective against MRSA but has limited activity against some strains of streptococcus that are resistant to